2. Inhibitory Antibodies
  3. Virus Neutralizing Antibodies

Virus Neutralizing Antibodies

Virus Neutralizing Antibodies (117):

Cat. No. Product Name Purity Image
  • HY-P9944
    Palivizumab 99.63%  
    Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice.
    (2)
  • HY-P99756
    Nirsevimab 98.00%  
    Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections.
    (2)
  • HY-P99340
    Sotrovimab  
    Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease.
    (3)
  • HY-P99209
    Motavizumab 99.17%  
    Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.
    (2)
  • HY-P99804
    Clesrovimab 99.77%  
    Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection.
    (2)
  • HY-P992301
    Anti-RSV F Antibody (R4.C6)  
    Anti-RSV F Antibody (R4.C6) is a monoclonal antibody against RSV F, with a Kd of 0.34 nM for the post-fusion RSV F trimer. Anti-RSV F Antibody (R4.C6) recognizes a unique neutralizing epitope spanning epitopes II and IV on both pre-fusion and post-fusion RSV F. Anti-RSV F Antibody (R4.C6) can be used in studies related to respiratory syncytial virus infection.
    Anti-RSV F Antibody (R4.C6)
  • HY-P992175
    ADI-14448  
    ADI-14448 is a RSV prefusion fusion glycoprotein inhibitor and HMPV fusion glycoprotein inhibitor, with a Kd of 3.8 × 10-10 M for RSV preF. ADI-14448 binds to epitope III of RSV preF, thereby blocking viral infection. ADI-14448 neutralizes RSV subtype A and HMPV subtype A1. ADI-14448 can be used in studies related to respiratory syncytial virus infection and metapneumovirus infection.
    ADI-14448
  • HY-P992281
    Anti-Nucleocapsid Antibody (N-18)  
    Anti-Nucleocapsid Antibody (N-18) is an antibody targeting Nucleocapsid, a structural protein of coronaviruses. Anti-Nucleocapsid Antibody (N-18) is applicable to studies on SARS-CoV-2 infection.
    Anti-Nucleocapsid Antibody (N-18)
  • HY-P990015
    Tobevibart 99.39%  
    Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
    (1)
  • HY-P99556
    Tixagevimab 99.05%  
    Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor.
    (2)
  • HY-P99344
    Bamlanivimab 99.97%  
    Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab.
    (2)
  • HY-P99341
    Casirivimab 99.54%  
    Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms.
    (2)
  • HY-P990756
    Pemivibart 99.12%  
    Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody. Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
    (3)
  • HY-P99853
    Diridavumab 98.09%  
    Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus.
    (2)
  • HY-P99342
    Imdevimab  
    Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins.
    (1)
  • HY-P991446
    MEDI-8852  
    MEDI-8852 is a human IgG1 monoclonal antibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    MEDI-8852
  • HY-P99564
    Teropavimab 99.70%  
    Teropavimab (3BNC117-LS) is a neutralizing antibody against HIV-1. Teropavimab can be used for the research of HIV infection.
    (2)
  • HY-P99604
    Cilgavimab  
    Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection.
    (1)
  • HY-P99103
    Bebtelovimab  
    Bebtelovimab a human IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19 ((the IC50 value for SARS-CoV-2/MT020880.1 virus is 9-22.1 ng/mL)). Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy.
    (1)
  • HY-P99277
    Actoxumab 99.52%  
    Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB.
    (1)